ACCME Media Statement on FDA Public Advisory Committee Meeting on ER/LA Opioid Analgesics REMS, May 3– 4, 2016

May 2, 2016
Posted by: 
Tamar Hosansky

Promoting Public Health with Accredited Continuing Education

“We share the deep concerns of the FDA about the growing epidemic of opioid abuse, addiction, and overdose – and we are committed to leveraging the power of education to improve prescriber practice and to promote safe and effective care for patients. We appreciate the FDA’s recognition of the value of accredited continuing education (CE) in carrying out this critical public health initiative. In response to this initiative, the CE community has conducted about 650 educational activities, educating close to 168,000 healthcare professionals. We believe that accredited CE has made — and can continue to make — significant contributions to addressing the patient safety issues identified in the ER/LA Opioid Analgesics REMS. Through thoughtful engagement in continuing education, clinicians improve their self-awareness; their ability to successfully work in teams; and the effectiveness, safety, and efficiency of the care they provide to patients.  We value our engagement with the FDA and look forward to continuing to work together to make a difference to patients, families, and communities across the country.” — Graham McMahon, MD, MMSc, President and Chief Executive Officer, Accreditation Council for Continuing Medical Education (ACCME®)

Download the full text of Dr. McMahon’s written comments.

For more information, visit CME in support of REMS.

Media Contact:  

Tamar Hosansky